2022 年博尔古省立和教学医院随访的成年艾滋病毒感染者的抗 SARS-CoV2 血清学概况及相关因素。

Journal of Infectiology Pub Date : 2024-01-08 DOI:10.29245/2689-9981/2023/2.1173

Attinsounon Cossi Angelo, Dovonou Comlan Albert, A. Kazali, Kanninkpo Fabius, A. Adébayo, Vodounou Amos, S. Khadidjatou, Serge Adé

{"title":"2022 年博尔古省立和教学医院随访的成年艾滋病毒感染者的抗 SARS-CoV2 血清学概况及相关因素。","authors":"Attinsounon Cossi Angelo, Dovonou Comlan Albert, A. Kazali, Kanninkpo Fabius, A. Adébayo, Vodounou Amos, S. Khadidjatou, Serge Adé","doi":"10.29245/2689-9981/2023/2.1173","DOIUrl":null,"url":null,"abstract":"Introduction: Literature data suggest that people living with the human immunodeficiency virus (PLHIV) are at increased risk of severe forms of Coronavirus 2019 (COVID-19) infection and related mortality. The aim of this study was to investigate the anti-SARS-CoV-2 serological profile in adults living with HIV followed at the Departmental and Teaching Hospital of Borgou (DTH-B) in 2022 and to identify factors associated with anti-SARS-CoV-2 seropositivity in the latter. Methods: This was a descriptive and analytical cross-sectional study conducted in the Internal Medicine Department at DTH-B, from June 27, 2022 to July 27, 2022. PLHIV were systematically recruited after informed consent. A survey form was used to collect epidemiological, clinical, paraclinical and therapeutic data. Anti-SARS-CoV-2 antibodies (IgG and IgM) were tested using the BIOSYNEX COVID-19 BSS rapid test (Biosynex SA, France). Data were analyzed using STATA/MP14.1 software. The significance level was 5%. Results: A total of 135 adults living with HIV were included in the study. The sex ratio was 0.34 and the mean age 45 ± 11.03 years. Anti-SARS-CoV-2 seroprevalence was 50.37%. Only one respondent reported a confirmed COVID-19, while vaccination coverage was 37.78%. Anti-SARS-CoV-2 seroprevalence in unvaccinated patients was 40.48%. Factors significantly associated with anti-SARS-CoV-2 seropositivity in multivariate analysis were vaccination status (p=0.02) and viral load (p=0.001). Conclusion: Anti-SARS-CoV-2 antibodies were detectable in more than half the PLHIV. Their presence was associated with the notion of vaccination and an undetectable viral load. This study therefore suggests the need to promote COVID-19 vaccination among PLHIV followed up at DTH-B, as well as the continuation of adequate management of HIV infection in order to reduce COVID-19-related morbidity and mortality in this so-called vulnerable population.","PeriodicalId":16100,"journal":{"name":"Journal of Infectiology","volume":"43 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anti-SARS-CoV2 serological profile and associated factors in adults living with HIV followed at Departmental and Teaching Hospital of Borgou in 2022.\",\"authors\":\"Attinsounon Cossi Angelo, Dovonou Comlan Albert, A. Kazali, Kanninkpo Fabius, A. Adébayo, Vodounou Amos, S. Khadidjatou, Serge Adé\",\"doi\":\"10.29245/2689-9981/2023/2.1173\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Literature data suggest that people living with the human immunodeficiency virus (PLHIV) are at increased risk of severe forms of Coronavirus 2019 (COVID-19) infection and related mortality. The aim of this study was to investigate the anti-SARS-CoV-2 serological profile in adults living with HIV followed at the Departmental and Teaching Hospital of Borgou (DTH-B) in 2022 and to identify factors associated with anti-SARS-CoV-2 seropositivity in the latter. Methods: This was a descriptive and analytical cross-sectional study conducted in the Internal Medicine Department at DTH-B, from June 27, 2022 to July 27, 2022. PLHIV were systematically recruited after informed consent. A survey form was used to collect epidemiological, clinical, paraclinical and therapeutic data. Anti-SARS-CoV-2 antibodies (IgG and IgM) were tested using the BIOSYNEX COVID-19 BSS rapid test (Biosynex SA, France). Data were analyzed using STATA/MP14.1 software. The significance level was 5%. Results: A total of 135 adults living with HIV were included in the study. The sex ratio was 0.34 and the mean age 45 ± 11.03 years. Anti-SARS-CoV-2 seroprevalence was 50.37%. Only one respondent reported a confirmed COVID-19, while vaccination coverage was 37.78%. Anti-SARS-CoV-2 seroprevalence in unvaccinated patients was 40.48%. Factors significantly associated with anti-SARS-CoV-2 seropositivity in multivariate analysis were vaccination status (p=0.02) and viral load (p=0.001). Conclusion: Anti-SARS-CoV-2 antibodies were detectable in more than half the PLHIV. Their presence was associated with the notion of vaccination and an undetectable viral load. This study therefore suggests the need to promote COVID-19 vaccination among PLHIV followed up at DTH-B, as well as the continuation of adequate management of HIV infection in order to reduce COVID-19-related morbidity and mortality in this so-called vulnerable population.\",\"PeriodicalId\":16100,\"journal\":{\"name\":\"Journal of Infectiology\",\"volume\":\"43 11\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Infectiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29245/2689-9981/2023/2.1173\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infectiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29245/2689-9981/2023/2.1173","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

导言：文献数据表明，人类免疫缺陷病毒感染者（PLHIV）感染严重形式的冠状病毒2019（COVID-19）并导致相关死亡的风险增加。本研究旨在调查 2022 年在博尔古教学医院（DTH-B）接受随访的成年艾滋病毒感染者的抗 SARS-CoV-2 血清学特征，并确定与后者抗 SARS-CoV-2 血清阳性相关的因素。研究方法这是一项描述性和分析性横断面研究，于 2022 年 6 月 27 日至 2022 年 7 月 27 日在 DTH-B 内科进行。在获得知情同意后，系统地招募了艾滋病毒感染者。调查表用于收集流行病学、临床、辅助临床和治疗数据。使用 BIOSYNEX COVID-19 BSS 快速检测试剂盒（Biosynex SA，法国）检测抗 SARS-CoV-2 抗体（IgG 和 IgM）。数据使用 STATA/MP14.1 软件进行分析。显著性水平为 5%。结果本研究共纳入 135 名成年艾滋病病毒感染者。性别比为 0.34，平均年龄为 45 ± 11.03 岁。抗 SARS-CoV-2 血清阳性率为 50.37%。只有一名受访者报告确诊过 COVID-19，疫苗接种率为 37.78%。未接种疫苗患者的抗SARS-CoV-2血清流行率为40.48%。在多变量分析中，与抗 SARS-CoV-2 血清阳性率明显相关的因素是疫苗接种情况（p=0.02）和病毒载量（p=0.001）。结论半数以上的 PLHIV 检测到了抗 SARS-CoV-2 抗体。抗体的存在与疫苗接种和病毒载量检测不到有关。因此，这项研究表明，有必要在 DTH-B 跟踪的艾滋病毒感染者中推广 COVID-19 疫苗接种，并继续对艾滋病毒感染进行适当管理，以降低这一所谓易感人群中与 COVID-19 相关的发病率和死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Anti-SARS-CoV2 serological profile and associated factors in adults living with HIV followed at Departmental and Teaching Hospital of Borgou in 2022.

Introduction: Literature data suggest that people living with the human immunodeficiency virus (PLHIV) are at increased risk of severe forms of Coronavirus 2019 (COVID-19) infection and related mortality. The aim of this study was to investigate the anti-SARS-CoV-2 serological profile in adults living with HIV followed at the Departmental and Teaching Hospital of Borgou (DTH-B) in 2022 and to identify factors associated with anti-SARS-CoV-2 seropositivity in the latter. Methods: This was a descriptive and analytical cross-sectional study conducted in the Internal Medicine Department at DTH-B, from June 27, 2022 to July 27, 2022. PLHIV were systematically recruited after informed consent. A survey form was used to collect epidemiological, clinical, paraclinical and therapeutic data. Anti-SARS-CoV-2 antibodies (IgG and IgM) were tested using the BIOSYNEX COVID-19 BSS rapid test (Biosynex SA, France). Data were analyzed using STATA/MP14.1 software. The significance level was 5%. Results: A total of 135 adults living with HIV were included in the study. The sex ratio was 0.34 and the mean age 45 ± 11.03 years. Anti-SARS-CoV-2 seroprevalence was 50.37%. Only one respondent reported a confirmed COVID-19, while vaccination coverage was 37.78%. Anti-SARS-CoV-2 seroprevalence in unvaccinated patients was 40.48%. Factors significantly associated with anti-SARS-CoV-2 seropositivity in multivariate analysis were vaccination status (p=0.02) and viral load (p=0.001). Conclusion: Anti-SARS-CoV-2 antibodies were detectable in more than half the PLHIV. Their presence was associated with the notion of vaccination and an undetectable viral load. This study therefore suggests the need to promote COVID-19 vaccination among PLHIV followed up at DTH-B, as well as the continuation of adequate management of HIV infection in order to reduce COVID-19-related morbidity and mortality in this so-called vulnerable population.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Infectiology

自引率

0.00%

发文量